Saturday 17 October 2026
Export MIRM’s income statement to Excel — free account
Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024. In the quarter to June 2026, revenue grew 37.9%, EPS fell 783.3%, free cash flow fell 681.5% and total debt rose 142.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
80.14
2.25
−2.73%
Follow MIRM
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 4 | 6 | 6 |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | 0.00 | 8.47 | 6.59 | 5.83 | 7.61 |
Altman Z-Score |
— | — | — | — | (0.93) | (0.26) | 0.90 | 1.85 | 4.42 |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 132.73 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | (3.32) | (3.09) | (0.23) | (0.87) | 0.54 |
P/Operating CF |
— | — | — | — | (14.59) | (19.04) | (73.86) | (387.74) | 653.56 |
Beneish M-Score |
— | — | — | — | — | 0.89 | (1.69) | (2.76) | (2.46) |
P/B ratio |
— | — | — | — | 4.02 | 4.59 | 4.94 | 8.71 | 12.60 |
Price to Tangible BV |
— | — | — | — | 4.77 | 7.85 | 0.00 | 0.00 | 73.74 |
EV/Sales |
— | — | — | — | 0.00 | 8.33 | 6.69 | 5.92 | 7.47 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 1,011.60 |
EV/Operating CF |
— | — | — | — | (3.46) | (5.35) | (17.58) | 193.01 | 69.71 |
EV/FCF |
— | — | — | — | (3.46) | (5.33) | (13.70) | (127.19) | 130.27 |
Quick Ratio |
— | 21.22 | 8.92 | 12.56 | 3.75 | 2.71 | 4.07 | 2.83 | 2.46 |
Current Ratio |
— | 21.22 | 9.13 | 12.80 | 3.91 | 2.94 | 4.45 | 3.10 | 2.67 |
Net Debt/EBITDA |
— | 2.99 | 2.07 | 1.75 | 0.14 | 0.08 | (0.21) | (0.45) | (19.11) |
Debt/Assets |
0.00% | 0.00% | 2.22% | 20.87% | 44.74% | 40.13% | 47.39% | 45.93% | 36.76% |
Debt/Equity |
— | 0.00 | 0.02 | 0.29 | 1.10 | 1.00 | 1.23 | 1.37 | 0.98 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.07 | 0.24 | 0.37 | 0.51 | 0.69 |
Operating CF/Net income |
— | 0.02 | 0.75 | 0.86 | 1.58 | 0.89 | 0.43 | (0.12) | (2.39) |
Capex/Depreciation |
— | 0.00 | 140.50 | (0.36) | (31.97) | (0.09) | (1.68) | (0.83) | (0.04) |
Interest Coverage |
— | (241.75) | (24.53) | (311.33) | (9.86) | (8.21) | (7.23) | (6.12) | (1.54) |
| — | (30.69%) | (92.98%) | (68.29%) | (57.47%) | (103.46%) | (83.65%) | (37.08%) | (8.65%) | |
| — | (66.76%) | (52.90%) | (53.29%) | (31.37%) | (41.90%) | (32.70%) | (13.35%) | (3.09%) | |
ROIC |
— | 0.00% | (201.97%) | 0.00% | (113.49%) | (62.17%) | (25.38%) | (21.61%) | (5.74%) |
Return on Tangible Assets |
— | (35.03%) | (48.81%) | (47.12%) | (67.20%) | (107.32%) | (54.26%) | (32.89%) | (6.76%) |
Average Days of Receivables |
— | — | — | — | 62.31 | 113.65 | 133.11 | 84.82 | 86.35 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 686.74% | 138.64% | 55.06% | 41.74% | 35.71% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 309.44% | 115.58% | 78.27% | 60.03% | 49.30% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.17 | 0.39 | 0.37 | 0.31 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 120.63% | 35.05% | 18.79% | 14.38% | 13.70% |
Graham Net Nets |
— | — | — | — | (0.02) | (0.03) | (0.01) | (0.03) | 0.01 |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | (17.37%) | (20.80%) | (13.22%) | (4.47%) | (0.60%) |
Free Cash Flow Yield |
— | — | — | — | (27.45%) | (18.46%) | (7.42%) | (0.80%) | 0.75% |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.63 | 2.28 | 4.56 | 7.09 | 10.39 |
Operating CF per Share |
— | (0.41) | (3.43) | (3.53) | (4.38) | (3.55) | (1.74) | 0.22 | 1.11 |
Capex per Share |
— | (8.34) | (0.02) | (0.01) | (0.63) | (0.01) | (0.49) | (0.44) | (0.02) |
Free Cash Flow per Share |
— | (8.76) | (3.45) | (3.54) | (5.01) | (3.56) | (2.23) | (0.22) | 1.09 |
Cash per Share |
— | 57.80 | 10.16 | 9.18 | 5.16 | 4.48 | 7.00 | 5.90 | 7.64 |
Shareholders Equity per Share |
— | (19.26) | 11.35 | 6.82 | 3.96 | 4.20 | 6.08 | 4.75 | 6.27 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (19.26) | 11.35 | 6.82 | 3.96 | 4.20 | 6.08 | 4.75 | 6.27 |
Free Cash Flow |
— | (7.87) | (39.64) | (89.30) | (151.78) | (120.41) | (91.05) | (10.67) | 54.87 |
Working Capital |
— | 49.53 | 106.29 | 217.89 | 124.00 | 125.50 | 300.48 | 266.24 | 343.89 |
Capital Expenditures |
— | (7.50) | (0.28) | (0.22) | (19.02) | (0.28) | (20.11) | (20.99) | (0.95) |
Net Current Asset Value |
— | (17.31) | 103.00 | 167.58 | (7.85) | (20.64) | (10.41) | (52.33) | 21.56 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | 0.11 | 0.06 | 0.00 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | — | 0.00 | 0.48 | 0.61 | 3.54 | 16.92 | 22.20 | 13.95 |
Cash ROIC |
— | (22.72%) | (15.84%) | (19.66%) | (37.15%) | (27.66%) | (10.82%) | (1.31%) | 5.44% |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 5.65 | 4.05 | 4.61 | 5.17 |
Accounts Payable Turnover |
— | 0.00 | 0.18 | 0.19 | 0.31 | 1.39 | 5.84 | 7.41 | 8.27 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 3.50 | 3.37 | 3.65 | 4.24 |
Average Days of Payables |
— | 0.00 | 3,775.05 | 1,846.09 | 1,758.06 | 256.33 | 57.54 | 65.35 | 35.01 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 290.20 | 164.15 | 173.13 | 100.16 | 90.62 |
Average Receivables |
— | — | — | — | — | 13.63 | 45.98 | 73.13 | 100.81 |
Average Payables |
— | 1.81 | 1.81 | 3.25 | 6.16 | 8.93 | 8.05 | 11.02 | 12.12 |
Average Inventory |
— | — | — | — | — | 3.54 | 13.94 | 22.36 | 23.65 |
Average Assets |
— | 25.99 | 99.34 | 193.79 | 267.76 | 323.78 | 499.76 | 658.69 | 756.78 |
Average Common Equity |
— | 56.52 | 56.52 | 151.22 | 146.15 | 131.12 | 195.35 | 237.16 | 270.17 |
Columns are period end dates